Zusammenfassung
HIV hat drei Enzyme, die für eine therapeutische Intervention ausgenützt werden können: die reverse Transkriptase, die Proteinase und die Integrase. Während für die Testung der Inhibtion der Proteinase klinische Studien ab 1992/93 begonnen wurden, hat die Beeinflussung des HIV Wachstums durch Nukleosidanaloga durch die Hemmung der reversen Transskriptase ab 1986 zu ersten verwertbaren Ergebnissen geführt [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Mitsuya H, Broder S (1986) Inhibition of the in vitro infectivity and cytopathic effect of human T-Lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2’,3’-didesoxynucleosides. Proc Nat Acd Sci USA 83: 1911–1915
Nakashima H, Matsui T, Harada S, Kobayashi N, Matsuda A, Ueda T, Yamamoto N (1986) Inhibition of replication and cytopathic effect of human T cell lymphotropic virus type III/lymphadenopathy-associated virus by 2’-azido-3’-desoxythymidine in vitro. Antimicrob Agents Chemother 30: 933–937
Moore RD, Hidalgo J, Sugland BW, Chaisson RE (1991) Zidovudine and the natural history of the acquired immunodeficiency syndrome. N Engl J Med 324: 1412–1416
Larder BA, Darby G, Richman DD (1989) HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731–1734
Boucher CAB, O’Sullivan E, Mulder JW, Ramautarsing C, Kellam P, Darby G, Lange JMA, Goudsmit J, Larder BA (1992) Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency viruspositiv subjects. J Infect Dis 165: 105–110
Larder BA, Kellam P, Kemp SD (1991) Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS 5: 137–144
Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L (1989) Plasma viremia in human immunodeficiency virus infection. N Engl J Med 321: 1626–1631
Shirasaka T, Yarchoan R, O’Brien MC, Husson RN, Anderson BD, Kojima E, Shimada T, Broder S, Mitsuya H (1993) Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine dideoxycytidine, and didesoxyinosine: an in vitro comparative study. Proc Natl Acad Sci USA 90: 562–566
Sanger F, Nicklen S, Coulson AR (1977) DNA sequencing with chainterminating inhibitors. Proc Natl Acad Sci USA 74: 5463–5467
Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA (1992) Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256: 1 783–1790
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
von Brunn, A. et al. (1994). Resistenzbestimmung für HIV-1 für Nukleosidanaloga durch In-vitro-Kultur und gleichzeitige Nukleinsäurensequenzierung. In: Scharrer, I., Schramm, W. (eds) 24. Hämophilie-Symposion. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-79009-6_8
Download citation
DOI: https://doi.org/10.1007/978-3-642-79009-6_8
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-57999-1
Online ISBN: 978-3-642-79009-6
eBook Packages: Springer Book Archive